Podcasts about lnp

Ying Tam, Chief Scientific Officer at Acuitas Therapeutics, discusses the company's role in delivering the first personalized CRISPR gene editing treatment to an infant with CPS-1, achieving treatment in just six months from diagnosis. Tam shares insights on evolving lipid nanoparticle technology beyond COVID vaccines, including LNPs that allow for next-generation immune-targeting delivery that is 10x more potent, and progress in delivering genetic medicines to stem cells and solid tumors. He also addresses the challenges of repeat dosing, a new biodegradable LNP formulation, and expanding genetic medicine beyond the liver to treat blood disorders and cancer.

Does the Liberal party need a quota for women? The party faces a stark reality - just six women among 28 elected officials, we examine whether quotas are the answer to fixing the Liberal Party's gender problem. Plus a major update in the case of the accused college share house murderer, which could see him avoid the death penalty. And in headlines today More than 1300 incidents have been reported as heavy rainfall and strong winds lash the NSW coast; The US Senate has passed President Donald Trumps big tax and spending bill; US President Donald Trump has threatened to pull all of Elon Musks subsidies saying it would make him pack up and head back to South Africa; The jury in the Sean Diddy Combs sex trafficking trial has asked to review parts of Cassie Ventura's testimony; Managers at the British hospital where Lucy Letby murdered 7 infants have been arrested on suspicion of gross negligence manslaughter THE END BITSSupport independent women's media Check out The Quicky Instagram here GET IN TOUCHShare your story, feedback, or dilemma! Send us a voice note or email us at thequicky@mamamia.com.au CREDITS Hosts: Taylah Strano & Claire Murphy Guests: Jess Wang, NewsWire Federal Politics Reporter Audio Producer: Lu Hill Become a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

The LNP have released their first budget with a record spend on health, money for parents and great news for new home buyers. Queensland Treasurer David Janetzki told Peter Fegan on 4BC Breakfast, "When we were preparing this budget, we did go about it very seriously, we took it calmly and methodically, line by line and yesterday we wanted to get the right balance for Queensland to invest in the frontline, the jobs and services."See omnystudio.com/listener for privacy information.

The Crisafulli Government will release their first budget on June 24 and there's plenty on the line. Treasurer David Janetzki has already confirmed that the former Labor government's $1000 energy rebates will be scrapped. So how will they deliver lower energy prices? Shadow Treasurer Shannon Fentiman told Peter Fegan on 4BC Breakfast, "Before the election, I'm sure you remember David Crisafulli banging on about a cost-of-living crisis and he said, energy bills would be lower under the LNP." "He also said that if families are still struggling, energy rebates must continue, which I thought, that's a pretty strong statement from David Crisafulli, but now he actually is the Premier and in charge it would seem that he either is breaking his promise on rebates or he doesn't think families are struggling."See omnystudio.com/listener for privacy information.

Even Barnaby Joyce did more work as a fake envoy than Peter Khalil! After some bafflement about Tasmania, Emerald and Tom unpack Senator Dorinda Cox, the very first ever guest on Serious Danger, and her defection to Labor this week (11:20). What an r-slur (rat)! Then, a Guardian piece looks at what went wrong for the Greens at the federal election (49:56). Was Advance the Greens-killer or part of the reason the LNP became so toxic? No call to action this week, so a reminder from Griff not to search google for “Kevin Rudd Jeffrey Epstein”. ---------- Just released on Patreon - “Inside The Greens #9 : CPRS, Rudd-Gillard & the 2010 election” The show can only exist because of our wonderful Patreon subscriber’s support. Subscribe for $3/month to get access to our fortnightly subscriber-only full episode, and unlock our complete library of over SEVENTY past bonus episodes. https://www.patreon.com/SeriousDangerAU ---------- Links - LIVE IN BRISBANE - JUNE 21ST - ON SALE NOW WITH SPECIAL GUEST ELIZABETH WATSON-BROWN - https://www.eventbrite.com.au/e/serious-danger-w-emerald-moon-tom-ballard-live-in-brisbane-tickets-1384636748789 The Guardian’s analysis of Greens election results - https://www.theguardian.com/news/ng-interactive/2025/jun/02/what-went-wrong-for-the-greens-in-the-australian-election Produced by Michael Griffin https://www.instagram.com/mikeskillz Follow us on https://twitter.com/SeriousDangerAU https://www.instagram.com/seriousdangerau https://www.tiktok.com/@seriousdangerauSupport the show: http://patreon.com/seriousdangerauSee omnystudio.com/listener for privacy information.

The Highlights * Labor's re-election  * Bradfield recount - a celebration of the integrity of our voting system * Labor's Residential Battery Program - Minister Bowen re-commits to his election pledge of $2.3bn home and business BESS subsidy * Australia on track to see utility BESS increase 8x to 16GW by end 2027 The Lowlights * The Albanese Government approved the North West Shelf expansion. The decision will put 4.4 billion tonnes of carbon into the atmosphere in the coming decades. That's the equivalent of approving 12 new coal fired power stations * Queensland Deputy Premier rejecting a 450MW Wind farm and BESS - climate science denialism in the LNP strikes again The Big Story this week * China emissions peaked in March 2024, and now for 12 months have plateaued and marginally declined * 4MCY2025 thermal power generation in China down 3.6% yoy  * China installs 46GW of solar in just the single month of April 2025 What's coming up * A carbon market price path towards an Asian CBAM - new Climate Energy Finance report released next week

This week, Stephen Donnelly covers election results in the ACT, the NT, and Western Australia.First-time guest Louise Crossman is a Canberra based political strategist and former president of ACT Labor. She and Stephen discuss the ACT results, including the rise of independents and how Labor almost lost the seat of Bean.In the Northern Territory Ryan Neve explains how turnout for Labor in remote communities ensured big swings in Lingiari, and the impact a popular CLP Chief Minister had on the race in Solomon. Finally in Western Australia Priya Brown revisits her original predictions and wagers - Bullwinkel's surprising swing to Labor did indeed signal a nationwide triumph for Labor - even if it hurt Priya in the pocket. Join us for this joyful episode - and don't forget to book tickets for our live show if you live near Melbourne!May 29, 7pmThe Toff in Town52 Swanston St, Melbourne VIC 3000Team Leaders and Campaign Organisers - Message Us for 2 x Free TicketsCanvassers- Book Tickets Here.CHAPTERS:00:00 Episode Start03:01 The ACT06:26 Bean14:19 The Senate23:26 The NT24:41 Solomon29:19 Lingiari34:15 Territory Election40:11 Western Australia46:39 Bullwinkel49:22 Pearce52:58 Canning56:51 Tangney01:02:11 MooreNew episodes every Friday.Join our Patreon: https://www.patreon.com/c/SociallyDemocraticFollow Us on Socials:Facebook (https://tr.ee/9jGIOy)Instagram (https://www.instagram.com/sociallydemocratic)LinkedIn (https://tr.ee/YxyYJh)Twitter (https://x.com/SocialDemPod)Bluesky (https://tr.ee/EqdapC)YouTube (https://www.youtube.com/@DunnStreet)The presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and make the world a better place, look us up at: dunnstreet.com.au Support the showNew episodes every Friday. If you like the show, rate and review us on your favourite podcast app. Follow Us on Socials: Facebook (https://tr.ee/9jGIOy)Instagram (https://www.instagram.com/sociallydemocratic)LinkedIn (https://tr.ee/YxyYJh)Twitter (https://x.com/SocialDemPod)Bluesky (https://tr.ee/EqdapC)YouTube (https://www.youtube.com/@DunnStreet) The presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and make the world a better place, look us up at: dunnstreet.com.au

Well, wouldn't you know it - Albo has romped it home and is one step closer to taking his place in the honoured ranks like Hawkey and Keating!In this episode of :Let's Save The Governor-General", Clancy, Damo and Feeby discuss, dissect and debate the election results and the wider ramifications for both the ALP and the LNP!————————————Find us on Twitter at: https://www.twitter.com/letssavetheggListen to us on Anchor.FM - https://anchor.fm/letssavethegg/————————————Music by Ukulelvishttps://www.youtube.com/watch?v=BtPm4hb04r0————————————

Nuclear power - and political power games - break up the Liberal-National Coalition. National editor Dennis Shanahan tries to make sense of David Littleproud’s big breakup. Find out more about The Front podcast here. You can read about this story and more on The Australian's website or on The Australian’s app. This episode of The Front is presented by Claire Harvey, produced by Kristen Amiet and edited by Joshua Burton. Our team includes Lia Tsamoglou, Tiffany Dimmack, Stephanie Coombes and Jasper Leak, who also composed our music. See omnystudio.com/listener for privacy information.

Hi Social Democrats,We're taking your favourite centre-left podcast out of the studio for our first live audience recording — and you're invited.Join us to celebrate the historic landslide victory of the Albanese Labor government and the spectacular downfall of the Liberal Party.When: 7:00 pm, Thursday 29 May (doors open 6:15) Where: The Toff, 2nd Floor, Curtin House, 252 Swanston Street, Melbourne Tickets: $15 + booking fee – Limited to 110 seats. Book early to avoid missing out! Free entry for ‘Campaign Organiser' level Patreon members & a plus one. Email grace@dunnstreet.com.au to put your name on the door.Join host Stephen Donnelly and our special guests David Feeney (Westgarth Primary booth captain), Jessie McCrone (former Andrews Deputy Chief of Staff), Benita Kolovos (Victorian State Correspondent, Guardian Australia), and Reed Fleming (former Andrews & Ardern Digital Director) to unpack: How Labor won and why it mattered The Liberal Party's collapse Media hits and misses The digital strategy that helped deliver victoryPlus audience category nominationsWhether you're a political tragic or just want to keep bathing in the warm waters of victory, this special night is for you.Secure your seat now and be part of the celebration: BOOK YOUR TICKETS HERE.See you at The Toff,The Socially Democratic TeamSupport the showNew episodes every Friday. If you like the show, rate and review us on your favourite podcast app. Follow Us on Socials: Facebook (https://tr.ee/9jGIOy)Instagram (https://www.instagram.com/sociallydemocratic)LinkedIn (https://tr.ee/YxyYJh)Twitter (https://x.com/SocialDemPod)Bluesky (https://tr.ee/EqdapC)YouTube (https://www.youtube.com/@DunnStreet) The presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and make the world a better place, look us up at: dunnstreet.com.au

Welcome to the Personal Development Trailblazers Podcast! In today's episode, we get real about the storms we face and the strength it takes to rise above them.Ethan A. Poetic, a native of Coatesville, PA, now resides in Lancaster, PA. He is the CEO & Founder of Ethan A. Poetic, LLC, empowering people to overcome adversities, life's challenges, and hardships. After surviving a near-fatal car accident and high-risk surgery, he was declared a Walking Living Miracle.Ethan is a Keynote Speaker, Life Coach, Mentor, Mental Health Advocate, Self-Published Author, Certified Mediator, and Restorative Justice Facilitator. He inspires youth and adults through school programs, community events, and public speaking, drawing from his own experiences with poverty, single-parent upbringing, and the need for positive leadership.He's been honored with numerous awards and recognitions, including Pennsylvania Commonwealth Citations, a Proclamation from Lancaster City, features on WGAL TV, CBS 21, 6ABC News, LNP, WFMZ TV, and WiTF Radio, and the NAACP Community Engagement Award. He also received the Distinguished Alumni Award from HACC.Ethan's autobiography, “The Inspirational Story of Ethan A. Poetic,” is available in print, eBook, and audio on Amazon, Audible, Apple, Spotify, Target, Walmart, and more.Connect with Ethan Here: https://www.linkedin.com/in/ethanapoetic1/https://www.facebook.com/ethan.vaughn2/https://www.instagram.com/ethanpoetic23/https://www.youtube.com/@Ethanpoetic23https://www.tiktok.com/@ethanpoetic23https://ethanspeaks.com/Grab the freebie here: https://6abc.com/philly-proud-ethan-a-poetic-car-crash-survivor/14302428/===================================If you enjoyed this episode, remember to hit the like button and subscribe. Then share this episode with your friends.Thanks for watching the Personal Development Trailblazers Podcast. This podcast is part of the Digital Trailblazer family of podcasts. To learn more about Digital Trailblazer and what we do to help entrepreneurs, go to DigitalTrailblazer.com.Are you a coach, consultant, expert, or online course creator? Then we'd love to invite you to our FREE Facebook Group where you can learn the best strategies to land more high-ticket clients and customers. QUICK LINKS: APPLY TO BE FEATURED: https://app.digitaltrailblazer.com/podcast-guest-applicationDIGITAL TRAILBLAZER: https://digitaltrailblazer.com/

The new Liberal leader Sussan Ley has promised a fresh approach after the party's disastrous result in the federal election. But will the first female leader of the party really be able to bring it back from the brink and build a policy offering that's attractive to voters? Today, host of ABC TVs 7.30 Sarah Ferguson on the future of the Coalition's nuclear power plan and Labor's factional stoush that saw two ministers axed.  Featured: Sarah Ferguson, host of 7.30

A new Attorney-General, Plibersek demoted, Dreyfus and Husic to the backbench: the thinking behind Anthony Albanese’s reshuffle - and who’ll be new Liberal leader? Find out more about The Front podcast here. You can read about this story and more on The Australian's website or on The Australian’s app. This episode of The Front is presented and produced by Claire Harvey and edited by Tiffany Dimmack. Our team includes Kristen Amiet, Lia Tsamoglou, Joshua Burton, Stephanie Coombes and Jasper Leak, who also composed our music. See omnystudio.com/listener for privacy information.

The 2025 federal election is done and dusted but the full extent of the fallout from Labor’s landslide victory still remains to be seen. Join Julie Macken and Michael Walker as they return for the final installment of ‘This Is Not A Horse Race’ to unpack what exactly transpired along the election trail, what issues were explored and ignored and ask the Community Radio Network’s Political Reporter Noah Secomb - where to from here. Let us know your thoughts by emailing fma@cbaa.org.au See omnystudio.com/listener for privacy information.

3 - The LNP's China Syndrome by Australian Citizens Party

The fallout from the LNP's federal election loss continues, with claims now emerging that Peter Dutton's campaign was sabotaged from within. Former LNP MP for Dawson, George Christensen, told Gary Hardgrave on 4BC Drive, "I've never quite seen anything like that, where they start actively working against the leader in the middle of the campaign." "Quite bizarre stuff, but it just shows you how deep the rot that's set into the Liberal Party, sadly," Mr Christensen continued. See omnystudio.com/listener for privacy information.

A former state LNP director says the Liberal party's election campaign failed to articulate the values and beliefs of the party and Australians.See omnystudio.com/listener for privacy information.

On this weeks program Chris talks to Laura Aston about Wayfinder Labs about finding new ways to unlock potential so everyone has convenient access to safe and healthy transport, topics include systems thinking, Open Streets initiatives and finding ways to travel that are healthy, convenient and safe.Local news includes the weekend festival of electoralism, the floating signifier of now ex LNP leader, Peter Duttons bus getting wedged on a protected bike lane barrier in Pitt Street, Sydney, ongoing Elizabeth Street protected lanes media coverage with our previous 3CR program quoted in a news.com.au article, the example of College Street Cycleway outlasting both a NSW transport minister and now disgraced shock jock and a Coppin Street Cycling Corridor public meeting at 6.30pm, Monday 5th May, Central Club Hotel, Richmond.3CR's annual Radiothon fundraiser is coming! We need to raise a whopping $275,000 to keep the station afloat and with YOUR help, we know we can. No donation is too small (or big!), and all donations over $2 are tax deductible. 3CR is ‘Your Station, Your Voice' and we look forward to YOUR donation during June (or earlier if you can't wait!) 

Listeners! It' election day and I cannot be bothered so it's AI shownotes this week. Enjoy! Hosts: Joel Hill & Dave (Cooker Watcher Supreme)(00:00:00) Introduction & WelcomeJoel welcomes listeners and introduces guest host Dave, replacing Jack the Insider.Shoutout: CB Co Beer for election night viewing. Mention of a competition involving a boat trip.Election Calls to Action:Vote 1 Fiona Patton in the Victorian Senate, preference 2 Purple Pingers.(00:01:48) Tinfoil Tales Follow-Up: The Next Pope?Discussion on cooker theories about the next Pope (King Charles?).Lindsey Graham's tweet suggesting Donald Trump for Pope.00:02:38 Dave reads the tweet.Trump's blue suit vs. Obama's tan suit controversy revisited.Brief thoughts on the late Pope's legacy and potential successor.(00:04:37) Dave's Cooker Report: Cessnock & CPACDave attended a meeting with Joel Jammal ("Eyebrows") in Cessnock (his 8th visit).Jammal debriefed the local unnamed "Freedom Group" (often linked to One Nation) on his CPAC trip.Local Candidates Present:Stuart Bonds (One Nation candidate for Hunter).Jennifer Stefanak (Trumpet of Patriots Newcastle) - Flat Earther, aliens are fallen angels, won NCAT case after dismissal from child services. Not allowed to speak despite attending.Mysterious Host: Christine Stevens, credited by Jammal as "brains behind the Wollongbae Road campaign" (a local road widening project used by cookers).Stevens now campaign manager for Stuart Bonds (referred to as "boss"). Possible links to broader far-right organising.Joel Jammal's Gifts: Rolled-up maps for Cessnock's 6 cooker councillors showing ALP vs. Voice 'No' vote intersections. Maps available for purchase from Jammal.Jammal's CPAC Trip: Won the trip via the "Shark Bites Pitching Contest" at CPAC Australia (Sky paywall).Winners expected to produce content upon return.Included a communication seminar with Steve Bannon.Stuart Bonds' Candidacy (Hunter):Odds discussed ($10 on Sportsbet).Labor's Dan Repacholi favoured ($1.15).Bonds' history: 21% primary in 2019, left One Nation, rejoined. Consistent far-right vote in the region.Bonds' desire to "start a conversation about coal mining" (already ongoing).Discussion on Labor's telehealth plan and cooker opposition.(00:24:07) Trumpism & Dutton's CampaignDiscussion on the "blueprint for Trump 28".Chris LaCivita (Trump advisor) reportedly helped Peter Dutton's campaign. Joel questions the effectiveness given global trends.Mainstream media's difficulty rallying behind Dutton.(00:25:52) Cooker Report Part 2: Gosford & MyPlaceDave attended the Lisa Bellamy independent campaign launch in Gosford.Follow-on from "Coasties Who Care" (MyPlace environmentalist council ticket).Shadowy Figure: Kate Mason (anti-renewable circuit, IPA/Advance events). Launched Bellamy's campaign.Campaign barely mentions climate change, focuses on opposing Aboriginal Land Council developments.Key Figures on Stage:Jake Cassar (musician, prepper).Lisa Bellamy (MyPlace coordinator, seen at Convoy with Kate Mason).Vicki Burke (MyPlace food/water security organiser, believes in aliens/other planets).Group suggests increased One Nation vote would benefit them. Bellamy received ~3000 votes previously.Kate Mason's Agenda: Reshaping the environment movement to focus on conspiracies (15-min cities, anti-meat).Shapeshifted from anti-vax (IMOP) -> Voice 'No' -> Anti-artificial food/Bellamy campaign.Significant Telegram following despite "gobbledygook" posts.Rally vs. Darkinjung Land Council/Woolworths Development: Focus remains on Land Council projects. Racist undertones ("love the land as much as we do").Links to Garingai (now potentially split/rebranded). NRL Welcome to Country discussed.Jake Cassar Deep Dive: Constant self-promotion, minimal concrete environmental vision beyond opposing the Land Council. Attacks Labor/Greens. Right-wing presence at events. Ballarat missing person search (found dog with SES). Yowie encounter at Woy Woy tip. Lack of accountability in Facebook environmental groups (anti-immigration/Aboriginal rhetoric).(00:40:33) Monica Smit's Private Prosecution of Dan AndrewsMonica plans a private criminal prosecution against Dan Andrews (and Jacinta Allan).Website Quote: "The wait is over righteous justice begins now" - Monica Smit.Topher Field involved as cheerleader/promoter.Basis: "New evidence" (Document 34 FOI email) allegedly showing curfew decision made before consulting CHO Brett Sutton. Implication: tyranny, not health advice.Joel suggests it was likely capitulation to police enforcement ease.Fundraising: Claimed $124,605 raised (via manually updated widget). Monica paid herself $1000/week stipend already.Monica's Justification ("Why me?"): Stood toe-to-toe and won, relentless energy, prison time (refused bail), won appeal, resisted database handover, won unlawful arrest case (appealing costs decision), claims past refund integrity, lives simply, no distractions (children/friends).Bender (@SpambotX) Twitter Thread: Brutal takedown of Monica as a "despicable con woman".Highlights Consumer Affairs conviction ($66k pocketed from unregistered fundraiser).Accuses Topher Field of seeking a cut.Details legal failures, self-orchestrated "martyrdom", $250k legal bill after rejecting settlement.Criticises "journalism" and book ("Cell 22").Predicts prosecution failure and abandonment once donations dry up.Bender's Legal Analysis (Round 2):Private prosecution (Crimes Act s 321) needs prima facie case, not conspiracy.Document 34 likely inadmissible hearsay.Misconduct charge needs proof of knowing, malicious law-breaking (R v Quach).Lockdowns upheld (Loielo v Giles), backed by Public Health Act & CHO advice.DPP can shut down frivolous cases (Public Prosecutions Act s 22).Previous treason case tossed out.Criticises fundraising transparency (Fundraising Act 1998), $52k/year salary.Highlights past legal issues (incitement charges dropped, health order conviction, Judge Tran's comments).Past Precedent: 2021 private prosecution for treason (Anthony Herman) recalled - chaotic online hearing.Monica's Timeline & Updates:Initial plan: Assemble legal team by April 24, first meeting April 30.Reality (May 1): No team announced. Video claims it will take "a few weeks" to pick lawyers.Met with a lawyer ($500/hr, 2 hours booked).Posted picture near a waterfall instead of legal updates ("reset and reload").Now targeting Jacinta Allan as well.Promises refund of remaining balance if no prospect of success.Discussion on cooker lawyers (Matouk, Buckley). Monica's motivation seen as attention/clout chasing.(01:17:54) Return to The Cali (Caledonian Hotel, Singleton)Dave attended Pauline Hanson & Stuart Bonds event ($20 lunch that never happened).Low turnout (~45 people in beer garden). Regulars, pensioners, Chris Sky filming, James Ashby present.Stuart Bonds Guardian article discussed (misogyny, anti-vax, "Little Hitlers"). Worn as badge of honour.Homeschooling attempt due to "woke trans agenda".Red Ensign described as "real flag".Unregistered campaign trailer incident.Pauline Hanson: Speech built to "greatest hits" (Aboriginal industry). Mumbles less the longer she speaks.Cali Update: Corruption Whistleblower book sold at bar (credit card accepted). Eureka beer on tap (FJB beer rebranded/gone?). Frenchies brewery connection? Pub seems to be returning to normal operations, but Red Ensign still flies. Food looks good, beer selection poor (Lion Nathan). No coal miners attended the event despite Bonds' background.(01:36:30) Candidates Forum: Patterson (Port Stephens)Dave attended forum; ABC filming due to anti-wind turbine mob presence.Low turnout of protesters (~5 loud individuals). Meryl Swanson (Labor incumbent) well-prepared.Marginal seat: Libs (Lawrence Ancliffe), aligned Independent, One Nation, Trumpet, Family First running against Swanson.History of intimidation (boat incident during Mayoral campaign).Betting odds discussed (Labor $1.66, Coalition $2.37). YouGov poll (Labor 51.8%).Irony: Libs proposed nuclear plant at Port Stephens in 2007.Bizarre Moments:Trumpet candidate Peter Arena: Wind turbines interfere with missile detection; mentioned fighting audience member over wife littering.(01:42:37) Billy Bay vs GAP Feud UpdateDr. William Bay told people not to vote for GAP (Great Australian Party) despite running for them.Rod Culleton's response.Billy Bay's letter to Culleton: Mock SovCit style ("Office of Vexatious Litigants and Spiritual Audits"), demands apology, foot kissing, $8 trillion. Full of threats (librarian grievance, livestream in lab coat, seizing karma balance). Written on GAP letterhead.Feud background (payment disputes) covered previously by Tinfoil Tales.(01:46:51) Amelia Hamer (Liberal, Kooyong) vs The PeopleRecap: Fake renter scandal (owns 2 properties + trust fund beneficiary).A-Frame sign spamming controversy vs Monique Ryan (Teal MP).Council imposed one-sign limit due to safety/obstruction complaints.Liberals took council to Supreme Court over implied freedom of political communication.Court upheld freedom but allowed council safety enforcement (opaque outcome).Likely outcome: confrontations over sign placement. James Patterson claiming victory. Joel predicts local backlash.(01:51:08) Election Odds & PredictionsSportsbet: Labor $1.05, Coalition $9.50.YouGov: Labor 53 / Coalition 47 (2PP). Projecting 84 seats for Labor (75 needed for majority).Dickson (Dutton's seat): YouGov 50.2% LNP / 49.8% ALP. Sportsbet has Dutton favourite ($1.28 vs $3.35).Joel laments betting ban but expresses optimism for Labor win, potential Dutton loss.(01:53:29) Wrap Up & OutroJoel thanks Dave for his "invaluable" and "brave" cooker reporting.Standard Patreon plugs etc. skipped.Sign off & enjoy the election.

AI shownotes again. I'm sure they are totally accurate. Recorded: ANZAC Day (Australian Public Holiday)Hosts: Jack the Insider & Hong Kong JackIntroduction & ANZAC Day Reflections (00:00:01 - 00:01:17)Jack the Insider welcomes listeners to Episode 111, recorded on ANZAC Day.Mention of an interruption at the Melbourne Dawn Service involving neo-Nazi Jacob Hersant.Introduction of Hong Kong Jack.Hong Kong Update & Australian Politics (00:01:17 - 00:10:05)Hong Kong Exodus: Hong Kong Jack notes 2.2 million people left Hong Kong over Easter.Jacob Hersant Incident: Further discussion on the neo-Nazi escorted from the Shrine of Remembrance.Rise of Neo-Nazism & Fringe Candidates: Jack the Insider discusses the history (Jim Sallium) and current state of far-right politics, including candidates with criminal convictions (Rod Culleton, Dixon candidate) potentially running despite Section 44 eligibility issues.Section 44 Cases: Mention of Phil Cleary and a Greens candidate ("secret New Zealander").YouGov Poll Analysis:Labor: 33.5%LNP: 31%Greens: 14%One Nation: 10.5% (up significantly from ~5% in 2022)TPP: 53.5% (Labor) / 46.5% (LNP)Preference Flows: Discussion on One Nation's decision to preference LNP and historical preference flows to Labor. Challenges for minor parties getting How-To-Vote cards distributed (comparison to Democrats).Election Analysis & Predictions (00:10:05 - 00:20:42)Declining Two-Party System: Combined Labor/LNP primary vote down from the last election.LNP Strategy Critiqued: Jack the Insider criticizes the LNP for not adapting post-2022 election, particularly regarding teal seats and climate change.Campaign Trail: Albanese campaigning in Liberal marginals; Dutton's comments on Melbourne safety.Election Outcome Predictions:Jack the Insider: Labor majority (around 76-80 seats).Hong Kong Jack: Labor minority.Liberal Campaign Issues: Comparison to Latham's 2004 campaign, social media mishaps ("muppet heads"), vehicle emissions policy backflip.Betting Odds: Discussion on the shift in betting markets, favoring Labor.Early Voting: Debate on the merits and drawbacks of pre-polling, referencing Darren Hinch and Imre Selizynski's comments, and accessibility issues.Politics, Religion & Geopolitics (00:20:42 - 00:41:55)Preference Deals & Jewish Community: Discussion on Labor's preference deals with the Greens in McNamara (open ticket for Josh Burns) vs. Isaacs (Mark Dreyfus), causing concern in the Jewish community. Mention of the Adas Israel synagogue firebombing and surrounding uncertainties/rumours.Pope Francis's Passing: Reflections on his papacy. Hong Kong Jack prefers John Paul II; Jack the Insider defends Francis and criticizes JP II over handling scandals. Discussion on potential successors and the slow pace of change in the Catholic Church.Easter & Religion: Easter memes, the role of the Catholic Church (charity vs. criticism), changes in Ireland, Catholics selectively following doctrine (e.g., contraception).India-Pakistan Tensions: Escalation following a militant attack in Kashmir. India threatens to cut off water supplies to Pakistan. Historical context, nuclear capabilities, and the danger of water rights disputes. Brief mentions of Pakistan's internal issues and conditions in Bangladesh.US Politics & Global Affairs (00:41:55 - 00:55:28)Trump & Trade: Trump walks back China tariff threats after meeting retail executives concerned about Christmas stock. Discussion on Trump's understanding of trade.US Courts & Executive Orders: Judge Kollar-Kotelly's ruling striking down parts of Trump's order requiring citizenship proof for voter registration, while upholding other sections. Discussion on the proper role of courts, checks and balances, and Congress's inaction leading to increased reliance on executive orders.Russia-Ukraine Peace Proposal: Details of a proposed deal involving US recognition of Russian control over Crimea/Eastern regions, no NATO for Ukraine, lifting sanctions vs. European security guarantees for Ukraine, return of some territory, etc. Criticism from Boris Johnson; seen as unfavourable to Ukraine. Trump's tweet urging Putin to stop strikes on Kyiv.Anniversaries & Culture (00:55:28 - 00:58:31)Saigon Evacuation: 50th anniversary of the Australian Embassy evacuation, noting local staff left behind.Crocodile Dundee: 39th anniversary. Paul Hogan's comments, investment success stories (Dennis Lillee).Yahoo Serious: Mention of a current court case.Sports: Cricket, AFL & More (00:58:31 - 01:29:28)Keith Stackpole (RIP): Tribute to the former Australian cricketer. Discussion of his career as a player (opener, aggressive batsman) and commentator. Anecdotes involving Bill Lawry, Kerry O'Keeffe, Harsha Bhogle.AFL Send-Off Rule Debate: Sparked by the Nash/Miers incident. Arguments for/against a red card, implementation challenges (timing, concussion protocols), historical examples, Lee Matthews' view.MCG Security & SCG Fan Ban: Increased security for ANZAC Day game. Discussion on the SCG Trust's two-year ban on a 16-year-old fan for throwing/dropping a record near Aliir Aliir – deemed excessive by the hosts.Noah Balta Controversy: Richmond player playing before being sentenced for assault. Criticism of Richmond's handling, the AFL's stance, player's curfew impacting availability, and political commentary surrounding the issue.Tom De Koning Contract: Rumoured huge offer from St Kilda. Discussion on his value, the Gawn/Grundy comparison, implications for both clubs, and the changing role/importance of elite ruckmen.NRL: Broncos defeat Bulldogs; several Bulldogs players facing bans. Roosters vs Dragons ANZAC match preview.Rugby & Cricket Updates: James O'Connor's late-game heroics; Cameron Green's century on County debut for Gloucestershire; IPL viewing challenges.Final Thoughts (01:29:28 - End)Meat Consumption Trends: Rebound in meat buying over plant-based alternatives.Unnecessary Technology: Comparison of plant-based foods and internet-connected fridges.ANZAC Day AFL Game: 30th anniversary of the Essendon vs Collingwood match, origins involving Kevin Sheedy and Gabby Allen.Wrap-up & Sign-off.

In this mega-episode, Stephen Donnelly goes on a whirlwind tour of Australia's most hotly-contested seats for Labor. He is joined by campaign experts (see below) from each state, who shine a spotlight on the candidates, the constituents, and the issues shaping each electorate.They share the betting odds and lay their predictions on the table. This is the ultimate election night primer.***Use the Chapter headings to jump to the seats that pique your interest - or listen to the whole episode like the absolute beast you are.***Can Labor get to 76 this Saturday night? Join us to find out. CHAPTERS:00:00 Introduction01:18 Welcome to NSW06:00 Bennelong12:42 Gilmore21:51 Paterson29:52 Hunter34:48 Robertson41:47 Welcome to QLD45:39 Leichardt54:39 Bonner01:03:23 Brisbane01:08:51 Longman01:14:16 Welcome to TAS01:15:44 Lyons 01:30:27 Bass01:35:49 Franklin01:38:22 Welcome to the NT01:39:20 Solomon01:48:18 Lingiari01:56:35 Welcome to SA02:00:42 Boothby02:10:19 Sturt02:19:41 Welcome to WA02:25:13 Bullwinkle02:29:32 Tangney02:37:16 Pearce02:42:47 Canning02:48:58 Welcome to VIC02:52:58 Chisolm 03:00:58 Menzies03:03:19 Aston03:07:50 Dunkley03:10:33 Bruce03:11:59 McEwan03:15:21 Hawke03:17:37 Mcnamara03:29:08 Wills 03:40:27 Wrap UpSPECIAL GUESTS:NSW - Todd PinkertonTodd is the director of campaigns and strategy at Unions NSW, a former federal and state Labor staffer, and he's been on every campaign cycle since 2011.QLD - Evan MoorheadEvan is the director of Anacta Strategies, former Director of Strategy for the Office of the Premier and Minister for Trade, former State Secretary for Queensland Labor, and former State Member for Waterford.WA - Priya BrownPriya is a partner at GRA Partners, the former Chief of Staff in the WA Government, a former Senior Advisor in the Vic Government, and the former Regional Field Director for the Community Action Network.TAS - Jack MilroyJack is a senior strategist and public affairs professional with more than 20 years of experience in progressive political campaigns in Australia and abroad.SA - Matt ClemowMatt is a former Senior Advisor and Chief of Staff in the SA Labor Government, to successive SA Labor Premiers and current consultant for Capetal Advisory in Adelaide.NT - Ryan NeveRyan has over 20 years of experience as an advisor in the NT Government, as well as stints in the UK and Victoria. Most recently he was Executive Director for the Finance, Communications, Policy, and Strategy Divisions within the Dept. of Environment, Parks, and Water Security in the NT. VIC - Jessie McCroneJessie is a managing partner at FMRS advisory, the former Deputy Chief of Staff to Daniel Andrews, and former ALP National Organiser.The presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and Support the showNew episodes out every Friday.If you like the show leave a comment below or leave us a review on Podchaser: https://bit.ly/36uFbp8Support the show on Patreon. Follow us on YouTube, Facebook, X, Bluesky, and Instagram.

The latest crime figures suggest a 32 per cent drop in cases against children charged with at least one of an initial 13 offences included in the LNP's Adult Crime, Adult Time laws. Queensland Premier David Crisafulli told Peter Fegan on 4BC Breakfast, "I'm not for turning and my message to them is the same as my message to the Labor Party and that is we're goin to be passing the next wave of adult crime, adult time next month, with or without your support." "We've got a long way to go," Premier Crisafulli continued.See omnystudio.com/listener for privacy information.

Early voting is now open, and E-Day is drawing near!Stephen Donnelly, Jessie McCrone, and David Feeney are back to unpack the previous week. Both campaigns briefly paused for Easter and out of respect for the passing of Pope Francis. Who was helped, and who was hurt by this hiatus? The hosts are joined by former digital strategist for Daniel Andrews and Jacinda Ardern, Reed Fleming.  Reed reveals what both major parties (and a few minor ones) have spent on their social media campaigns - plus their messaging missteps and sometimes bizarre attempts to go viral.Everyone wonders what the LNP campaign would look like if Dutton could be to his inner Darth Vader. Plus - your listener nominations!Mentioned in the episode:Reed Fleming's Good to Go https://www.goodtogo.digital/The presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and make the world a better place, look us up at: dunnstreet.com.au Support the showNew episodes out every Friday.If you like the show leave a comment below or leave us a review on Podchaser: https://bit.ly/36uFbp8Support the show on Patreon. Follow us on YouTube, Facebook, X, Bluesky, and Instagram.

Chooks, the election is just over a week away, and early voting is open, so we're talking about some tools you can use to make sure your vote is representing you and your values! Plus, we're reacting to some primo, pizzazz-less LNP vids. LINKS Visit the Vote Compass website https://bit.ly/4lGnto1 Visit the Build A Ballot website https://www.buildaballot.org.au/ Check out @itsalotpod on IG at https://bit.ly/itsalot-instagram Review the podcast on Apple Podcasts https://bit.ly/ial-review Follow LiSTNR Entertainment on IG @listnrentertainment Follow LiSTNR Entertainment on TikTok @listnrentertainment CREDITS Host: Abbie Chatfield @abbiechatfield Executive Producer: Lem Zakharia @lemzakhariaDigital and Social Producer: Oscar Gordon @oscargordon Recording Engineer & Editor: Amy Kimball @amy.kimballSocial and Video Producer: Zoe Panaretos @zoepanaretosIt's A Lot Social Media Manager: Julia ToomeyManaging Producer: Sam Cavanagh Find more great podcasts like this at www.listnr.com/See omnystudio.com/listener for privacy information.

Yesterday Health Minister Mark Butler was forced to clarify that there will still be some patients who are charged a gap fee at the GP. Meanwhile at a state level, the LNP government are scrambling to redraw Queensland's hospital building plan after another scathing review. Australian Medical Association of Queensland President Dr Nick Yim told Luke Bradnam on 4BC Breakfast, "when the government did first make their announcement at the very start of the campaign... we've always said that it's quite unlikely that all GPs or 90 per cent of GPs will be bulk billing." "When we surveyed our members, they've told us that if they choose to universally bulk bill, that's actually going to be a loss of 20 to 30 per cent of their revenue." "I guess in this current climate, I'd ask any business owner, any workplace, it's very, very unlikely that medical practice could survive if they have a 20, 30 per cent reduction in revenue," Dr Yim said.See omnystudio.com/listener for privacy information.

Epic rap battles of history - Biggie vs Tupac, Kendick vs Drake, DJ Albo vs Peggy Sue. Emerald and Tom take a look at the week’s election news (10:57). Dual-citizenship takes down the Greens candidate for Franklin, and is Purple Pingers to blame for squatters in Carol’s empty house? Then they are joined by the MP for Griffith and Greens housing spokesperson, Max Chandler-Mather! (26:13) Is this the week the major parties went mask off? Will the competing Labor and LNP housing policies just compete to do the most damage? Why do the Greens want a public developer? Finally, a call to action (1:03:33). ---------- Just released on Patreon - “Inside The Greens #9 : The Rudd years, GFC, Ronan Lee & a Lib-Green Love Affair” The show can only exist because of our wonderful Patreon subscriber’s support. Subscribe for $3/month to get access to our fortnightly subscriber-only full episode, and unlock our complete library of over SEVENTY past bonus episodes. https://www.patreon.com/SeriousDangerAU ---------- Call to action - Support Max’s campaign - https://www.maxchandlermather.com/ Purple Pingers article -https://www.abc.net.au/news/2025-04-16/purple-pingers-jordan-van-den-lamb-squatters-post-senate-elex/105150596 THE ELECTION IS HERE! Go to this page, contact your local campaign - https://greens.org.au/events Sign up to volunteer greens.org.au/vic/volunteer Serious Danger merch - https://seriousdanger.bigcartel.com/ Produced by Michael Griffin https://www.instagram.com/mikeskillz Follow us on https://twitter.com/SeriousDangerAU https://www.instagram.com/seriousdangerau https://www.tiktok.com/@seriousdangerauSupport the show: http://patreon.com/seriousdangerauSee omnystudio.com/listener for privacy information.

This Week:Labor and the Liberals officially launch their campaigns.Peter Dutton's son Harry speaks for the average worker.Shadow Minister for Education Sarah Henderson wants to gut Free TAFE.And Jacinta Nampijinpa Price wants to Make Australia Great Again, but not like that. Obviously. Stephen Donnely, Jessie McCrone, and David Feeney have a lot to cover this week. They are joined by Victorian State Correspondent for Guardian Australia, Benita Kolovos, who gives a journo's-eye-view of life on the campaign trail. Plus your listener nominations!Mentioned in the episode:Socially Democratic's Solidarity Online Phone Banking Registration: https://thisislabor.org/get-involved/attend-an-event/socially-democratic-online-phone-bank/The presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and make the world a better place, look us up at: dunnstreet.com.au Support the showNew episodes out every Friday.If you like the show leave a comment below or leave us a review on Podchaser: https://bit.ly/36uFbp8Support the show on Patreon. Follow us on YouTube, Facebook, X, Bluesky, and Instagram.

Amazed though I am, it appears the LNP has one policy which is so critical it should win the election. I am talking about Gas reverse tariffs. Recall that while East Coast Australia has doubled its gas production over the past decade, the domestic market has been supplied with 25% less gas. This has driven … Continue reading "Gas: One Policy To Rule Them All!…"

Marama Labs, a rapidly growing scientific instrumentation innovator, announces the launch of its revolutionary new CloudSpec instrument for nanomedicine developers. CloudSpec's patented technology slashes development times for advanced nanoparticle drug formulations used in gene therapies, vaccines, and cancer treatments. Lipid Nanoparticle (LNP) therapies are a hugely valuable class of biopharmaceutical nanomedicines; their use in Covid vaccines demonstrated the power and speed-to-market that RNA-loaded LNPs enable. The LNP market is expected to grow 7x within the next 10 years, as new therapies are developed for some of the hardest-to-drug diseases in cancer, genetic disorders and even the common cold. CloudSpec accelerates LNP development by solving a critical bottleneck - quantifying the drug payload in seconds - while current methods take hours. Breaking the bottleneck in nanomedicine development LNPs are tiny insoluble particles embedded with RNA or DNA. They are difficult to analyse directly due to their small size and light-scattering properties. CloudSpec's Scatter-Free Absorption (SFA) technology enables fast and accurate results using a new approach based on easy-to-use UV analysis. CloudSpec eliminates the need to break up the particles for analysis and doesn't require hard-to-use fluorescent dyes. CloudSpec measurements take 15 seconds compared to 2 hours using existing methods. By measuring intact particles, CloudSpec provides results from sample to answer in just a few minutes. CloudSpec is expected to revolutionise how lipid nanoparticles are analysed and quantified. "We are thrilled to introduce the CloudSpec instrument to the market," said Brendan Darby, CEO of Marama Labs. "This innovative technology represents a significant advancement in the field of nanomedicine, and we are confident that it will transform research with lipid nanoparticles." "We worked with some of the leading names in RNA-LNP biopharma to develop CloudSpec for this market. It has received a hugely positive response from our users, who are desperate to get away from the current slow, labour-intensive and inaccurate fluorescence measurements. CloudSpec gets them over the drug assay bottleneck and will speed up delivery to market", said Darren Andrews, CCO of Marama Labs. CloudSpec's launch to market will be spearheaded by a webinar on 7 May 2025 from two of CloudSpec's users from our Early Access Programme - Dr. Emily Young of 4basebio (UK) and Dr. Johanna Simon of Merck KGaA (Germany). Registration for the webinar is available here https://beacon-intelligence.com/webinar/rna-dna-quantification-in-lnps/. For more information about CloudSpec and its capabilities, please visit our website at www.maramalabs.com.

Tom is joined by Greens federal Senator for Tasmania and self-proclaimed best gamer in the Senate, Nick McKim! First up, the election has finally been announced for Saturday May 3rd (5:49). What is Nick’s review of the Albanese gov? Are Greens making a mistake by ruling out forming a minority with Dutton? Then, it’s time for Budget Winners and Losers 2025! (27:54) Is there anything good on offer? What were the LNP and Greens responses? Finally, a call to action (1:10:09). Also, the salmon scandal! ---------- Just released on Patreon - “The CFMEU scandal from the inside ft. Elizabeth Doidge” The show can only exist because of our wonderful Patreon subscriber’s support. Subscribe for $3/month to get access to our fortnightly subscriber-only full episode, and unlock our complete library of over SIXTY past bonus episodes. https://www.patreon.com/SeriousDangerAU ---------- Call to action - THE ELECTION IS HERE! Go to this page, contact your local campaign >> https://greens.org.au/events Folks in Lutruwita / Tasmania: Saturday April 5th - Skate for the Skate https://contact-tas.greens.org.au/civicrm/event/register?id=20835&reset=1 Sunday April 6th - Greens for a Free Palestine https://contact-tas.greens.org.au/civicrm/event/register?id=20882&reset=1 Serious Danger merch - https://seriousdanger.bigcartel.com/ Produced by Michael Griffin https://www.instagram.com/mikeskillz Follow us on https://twitter.com/SeriousDangerAU https://www.instagram.com/seriousdangerau https://www.tiktok.com/@seriousdangerauSupport the show: http://patreon.com/seriousdangerauSee omnystudio.com/listener for privacy information.

On May 3rd, just five weeks from now, Australians will be heading to the polls. The campaigning is underway after a visit to the Governor General by the Prime Minister. So, who will convince Australians they deserve to lead the country for the next three years, Anthony Albanese or Peter Dutton? It's an election with key policy differences so far all about the cost of living and energy policy.  Today, election analyst Casey Briggs explains why there's a growing number of swing voters.He's been looking at what they're thinking as politicians begin the hard sell.  We want you to help shape ABC News Daily's coverage of this election campaign. Send us a short voice memo telling us what's caught your attention in this campaign. We'll dedicate one episode each week of the campaign to explain a policy area and the politics around it with an expert or a journalist. We need topics and policies that a lot of people will be interested in. Email us: abcnewsdaily@abc.net.auFeatured: Casey Briggs, ABC election analyst

DJ Adam Bandt hits the decks with Abbie Chatfield. Emerald and Tom take a look at new polling about the election (11:33). Are the Greens going to lose their Brisbane seats or was it just a “poll-shaped object?” And what does Adam Bandt’s “sub-zero” popularity mean for the party? Then, policy!?! (46:05) Greens want to end gas and homelessness, Labor wants a $25 cap on meds, and LNP have gone full boonta (aka approve more gas, ban protests and hold a referendum). Finally, a call to action (1:12:42). ---------- Just released on Patreon - “The CFMEU scandal from the inside ft. Elizabeth Doidge” The show can only exist because of our wonderful Patreon subscriber’s support. Subscribe for $3/month to get access to our fortnightly subscriber-only full episode, and unlock our complete library of over SIXTY past bonus episodes. https://www.patreon.com/SeriousDangerAU ---------- Call to action - Greens rally in Brisbane - Keep Brisbane Green, Keep Dutton Out - https://elizabethwatsonbrown.com/duttonout March in March - happening today! - https://marchforforests.org/ Serious Danger merch - https://seriousdanger.bigcartel.com/ Produced by Michael Griffin https://www.instagram.com/mikeskillz Follow us on https://twitter.com/SeriousDangerAU https://www.instagram.com/seriousdangerau https://www.tiktok.com/@seriousdangerauSupport the show: http://patreon.com/seriousdangerauSee omnystudio.com/listener for privacy information.

In this first episode in a series of conversations with lawyers turned political candidates, ahead of the 2025 federal election, we sit down with the 30-year-old King & Wood Mallesons solicitor running to keep the Gold Coast seat of McPherson in Liberal-National hands. Host Jerome Doraisamy speaks with LNP candidate Leon Rebello, a former ministerial staffer who has worked at KWM as a solicitor for the past six years, about his upbringing and the values his family instilled in him, how work as a practitioner in foreign investment has shaped his views about the role of government, and the headline issues and challenges he is hearing on the ground from Gold Coast constituents. Rebello also discusses the importance of having all generations represented in our nation's capital, how his legal background will aid him if elected as a member of Parliament, and what excites him about the future of Australia. If you like this episode, show your support by  rating us or leaving a review on Apple Podcasts (The Lawyers Weekly Show) and by following Lawyers Weekly on social media: Facebook, Twitter and LinkedIn. If you have any questions about what you heard today, any topics of interest you have in mind, or if you'd like to lend your voice to the show, email editor@lawyersweekly.com.au for more insights!

LNP is back. Tonight, J talks about the recently vandalized Newcomb's Ranch and how the ACH community was there to step in and help clean up. What's next for NR & GVBC? J takes your questions.Assistant Director of the Los Angeles Sheriff's Department, and friend to The Ryan's, MIKE LEUM is here to tell us all what it's like r3ponding to calls on Angeles Crest Highway, and all over the world. His task force responds internationally. How has the ACH community changed over the years? Is it better since GVBC? Worse?Viewer Mail: boxes have arrived from Chilao to New Jersey and there's no more room under J's desk… we have some unboxing to do.Plus Producer Arielle &new LNP merchandise and life gets real again his week! Thank you for being with us. Love one another. Live it while ya got it.#latenightplayset

Our Journalist roundtable for Feburary 14 included WVIA agriculture reporter Isabela Weiss and LNP's Jaxson White. Isabela discussed the budget address and its effect in agriculture in western Pa. Jaxson discussed an overview of the budget address and a look ahead to the legislative budget hearings in Harrisburg. Listen to the podcast to hear the full conversation. Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Advance Australia vs Serious Danger. Emerald and Tom turn on tethering and chat about the government’s election announcement to ‘finish’ the NBN (13:21). Fibre to the what now? Then a look at the rest of this week’s election news (33:31) - Dutton launches the LNP campaign, and Greens discuss power sharing, education and climate policies, while Labor and LNP are getting their muckraking agencies together. Finally, a call to action (1:02:16). ---------- Just released on Patreon - another instalment of Inside the Greens: Chapter 7: Tampa, Telstra, 9/11 The show can only exist because of our wonderful Patreon subscriber’s support. Subscribe for $3/month to get access to our fortnightly subscriber-only full episode, and unlock our complete library of over SIXTY past bonus episodes. https://www.patreon.com/SeriousDangerAU ---------- Call to action - Invasion Day rallies - https://antar.org.au/issues/survival-day/events-listing/ PLEASE take our 2025 Listener Survey (literally 5 minutes) - https://docs.google.com/forms/d/e/1FAIpQLSe0t7kV3e9sJ9aqhrCYSSf51KsAD_eqWKF-wjasGfQUeUSjwQ/viewform?usp=sharing Serious Danger merch - https://seriousdanger.bigcartel.com/ Produced by Michael Griffin - https://www.instagram.com/mikeskillz Follow us on - https://twitter.com/SeriousDangerAU https://www.instagram.com/seriousdangerau https://www.tiktok.com/@seriousdangerauSupport the show: http://patreon.com/seriousdangerauSee omnystudio.com/listener for privacy information.

Queensland’s new adult crime, adult time laws are facing their first test – but a legal loophole could see them fall at the first hurdle. Find out more about The Front podcast here. You can read about this story and more on The Australian's website or on The Australian’s app. This episode of The Front is presented and produced by Kristen Amiet, and edited by Tiffany Dimmack. Our regular host is Claire Harvey and original music is composed by Jasper Leak. See omnystudio.com/listener for privacy information.

Australians are guaranteed to head to the polls in the first five months of 2025.And while high interest rates and cost of living pressures are expected to be the top concerns for both major parties and voters, the battleground itself will also look different, with new changes to electoral seats and boundaries. Today, the ABC's Chief Elections Analyst Antony Green speaks with ABC News Radio's Tom Melville about why the next parliament is set to change.Featured: Antony Green, ABC Chief Elections Analyst

Headlines: Chaos in New Orleans as a truck strikes New Year’s revellers leaving 10 dead, three Virgin Australia staff stuck in their hotel after an incident at Nadi airport, and the LNP claims 10,000 businesses will collapse before the next parliamentary sitting. Best of Deep Dive: A network of volunteer doctors in Australia are stepping up to provide free medical care for Palestinians who have fled Gaza. From performing surgeries on patients with amputated limbs to treating chronic illness, they are filling the gaps where our government has fallen short, largely due to the visas provided for those fleeing not allowing access to healthcare. One of these doctors is Dr Mohamed Amr. He co-founded the Palestinian Australian New Zealand Medical Association (PANZMA). As part of The Briefing’s Best of Summer Series, we revisit Antoinette Lattouf’s exclusive conversation with Dr Amr from November last year. Follow The Briefing:TikTok: @listnrnewsroomInstagram: @listnrnewsroom @thebriefingpodcast YouTube: @LiSTNRnewsroomFacebook: @LiSTNR NewsroomSee omnystudio.com/listener for privacy information.

Nightlife News Breakdown with Philip Clark, joined by Amy Remeikis, Chief Political Analyst at the Australia Institute.

In this episode, the hosts dive into a variety of thought-provoking topics. Trevor kicks off with a story about Mailchimp banning his email service due to an article critical of Israel, sparking a discussion on the challenges of sharing controversial content. Scott then discusses President Biden's controversial decision to pardon his son, Hunter Biden, for tax and firearms felonies, comparing it to previous political scandals. Trevor shares an amusing anecdote about visiting an old-school barbershop. The conversation takes a serious turn as they discuss proposed legislation in Queensland to impose mandatory life sentences for children as young as ten, raising concerns about the impact on youth offenders and the justice system. They also satirically critique the Courier Mail's portrayal of youth crime and the LNP's economic recovery efforts. The episode wraps up with a discussion on France's decision not to arrest Netanyahu despite previous statements and a debate on the effectiveness of democracy versus dictatorship, reflecting on historical and current examples of political systems and their impact on society.To financially support the Podcast you can make:a per-episode donation via Patreon or one-off donation via credit card; orone-off or regular donations via Paypal orif you are into Cryptocurrency you can send Satoshis. We Livestream every Monday night at 7:30 pm Brisbane time. Follow us on Facebook or YouTube. Watch us live and join the discussion in the chat room.You can sign up for our newsletter, which links to articles that Trevor has highlighted as potentially interesting and that may be discussed on the podcast. You will get 3 emails per week. After the fiasco mentioned in episode 454 I can't use Mailchimp anymore so for the moment, send me an email and I'll add you to a temporary list until something more automated is arranged.We have a website. www.ironfistvelvetglove.com.auYou can email us. The address is trevor@ironfistvelvetglove.com.auYou can send us a voicemail message at SpeakpipeTranscripts started in episode 324. You can use this link to search our transcripts. Type "iron fist velvet glove" into the search directory, click on our podcast and then do a word search. It even has a player which will play the relevant section. It is incredibly quick.

最近昆州的州選舉中，鄉郊自由黨(LNP)擊敗執政達九年的工黨。

Nightlife News Breakdown with Philip Clark, joined by Emily Barrett, Managing Editor from The Saturday Paper. 

Queensland votes for change - after 9 years of Labor rule. It was a long night but the LNP will form a majority government. There were big swings against Labor in the regions and suburbs – and it was a bad night for the Greens. Plenty of lessons – and warning signs – ahead of the coming federal contest.David Speers is joined by Patricia Karvelas, Anthony Galloway, and Clare Armstrong. Casey Briggs runs the numbers in Queensland and looks ahead to the United States' election.Our guests are the outgoing Queensland Labor Deputy Premier Cameron Dick and Federal Nationals MP Keith Pitt.

In 2018, Queensland decriminalised abortion up to 22 weeks' gestation without a doctor's permission. Now, the prospect of repealing those laws has become a major issue ahead of this weekend's state election.In South Australia too, the legality of abortion has been contested in the parliament. So, why is abortion up for debate? Today, Prudence Flowers from Flinders University on why what's happening here can be linked to the United States.  Dr Flowers explains that the overturning of Roe v Wade in the US has sent shock waves globally, influencing debates in Australia. She says the political landscape in Queensland is particularly volatile, with independent MP Robbie Katter pushing for a repeal of the decriminalisation law. She notes the significant anti-abortion sentiment within the Liberal National Party, which could impact the outcome if they win the election. In South Australia, recent legislative attempts to restrict abortion have narrowly failed, reflecting the contentious nature of the issue. Featured: Dr Prudence Flowers, senior lecturer at Flinders UniversityKey Topics:Queensland abortion lawsSouth Australia abortion debateRoe v WadeRobbie KatterLiberal National Party and abortionUS influence on Australian politicsReproductive rightsPolitical strategies in electionsAbortion laws

Dunn Street founder and Community Organiser Stephen Donnelly was joined once again by former Queensland Treasurer, Jackie Trad, and former QLD Labor Campaign Director, Evan Moorhead.With four days (as of recording) to go until E-day in Queensland, our panel covers the latest polling, the first cracks in the LNP campaign and its impact on voters, and seat analysis of battleground electorates regions of Cairns, the Gold Coast and Logan, plus our Tory with a Typewriter award.Wanna make a difference this election? Find out how here: https://queenslandlabor.org/volunteer/ Join the Socially Democratic Patreon: https://tinyurl.com/45bc4wubThe presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and make the world a better place, look us up at: dunnstreet.com.au Support the show

It's something of a spring election season; Canberra voters go to the polls this weekend, while Queenslanders will cast their votes in a little over a week.  Federal politicians are watching closely for any indicators of the electoral mood.Queensland will be a key state in next year's federal election and the state poll will be telling. Labor has been in power for nearly a decade and the relatively new Premier Steven Miles is seeking the ALP's fourth term in office. But all signs point to a defeat for Labor and Opposition Leader David Crisafulli leading the LNP back into government.Melissa Clarke, filling in for David Speers, speaks to Kos Samaras and Tony Barry from Redbridge Group about the mood in the electorate. 

Dunn Street founder and Community Organiser Stephen Donnelly was joined by former Queensland Treasurer, Jackie Trad, and former QLD Labor Campaign Director, Evan Moorhead.They join Stephen for our first of four weekly recap episodes analysing the October Queensland state election campaign.Jackie and Evan lend their campaign expertise on everything QLDpol and discuss the diversity of the Queensland political landscape, current polling, how Labor will frame up the LNP's Crisafulli, and the key issues that will decide this election.Wanna make a difference this election? Find out how here: https://queenslandlabor.org/volunteer/ Join the Socially Democratic Patreon: https://tinyurl.com/45bc4wubThe presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and make the world a better place, look us up at: dunnstreet.com.au Support the show

LNP leads Labor by 10 points before the Queensland election, Kamala Harris roasted over Oprah Winfrey interview while some Hollywood stars praise her. Plus, Michigan Mayor Amer Ghalib endorses presidential candidate Donald Trump.See omnystudio.com/listener for privacy information.